The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement

Simple item page
dc.contributor.authorMizera, Jancs
dc.contributor.authorGenzor, Samuelcs
dc.contributor.authorSova, Milancs
dc.contributor.authorStanke, Ladislavcs
dc.contributor.authorBurget, Radimcs
dc.contributor.authorJakubec, Petrcs
dc.contributor.authorVykopal, Martincs
dc.contributor.authorPobeha, Pavolcs
dc.contributor.authorZapletalová, Janacs
dc.coverage.issue1cs
dc.coverage.volume16cs
dc.date.accessioned2024-05-13T10:45:49Z
dc.date.available2024-05-13T10:45:49Z
dc.date.issued2024-02-05cs
dc.description.abstractRationalePersistent respiratory symptoms following Coronavirus Disease 2019 (COVID-19) are associated with residual radiological changes in lung parenchyma, with a risk of development into lung fibrosis, and with impaired pulmonary function. Previous studies hinted at the possible efficacy of corticosteroids (CS) in facilitating the resolution of post-COVID residual changes in the lungs, but the available data is limited.AimTo evaluate the effects of CS treatment in post-COVID respiratory syndrome patients.Patients and methodsPost-COVID patients were recruited into a prospective single-center observational study and scheduled for an initial (V1) and follow-up visit (V2) at the Department of Respiratory Medicine and Tuberculosis, University Hospital Olomouc, comprising of pulmonary function testing, chest x-ray, and complex clinical examination. The decision to administer CS or maintain watchful waiting (WW) was in line with Czech national guidelines.ResultsThe study involved 2729 COVID-19 survivors (45.7% male; mean age: 54.6). From 2026 patients with complete V1 data, 131 patients were indicated for CS therapy. These patients showed significantly worse radiological and functional impairment at V1. Mean initial dose was 27.6 mg (SD +/- 10,64), and the mean duration of CS therapy was 13.3 weeks (SD +/- 10,06). Following therapy, significantly better improvement of static lung volumes and transfer factor for carbon monoxide (DLCO), and significantly better rates of good or complete radiological and subjective improvement were observed in the CS group compared to controls with available follow-up data (n = 894).ConclusionBetter improvement of pulmonary function, radiological findings and subjective symptoms were observed in patients CS compared to watchful waiting. Our findings suggest that glucocorticoid therapy could benefit selected patients with persistent dyspnea, significant radiological changes, and decreased DLCO.en
dc.formattextcs
dc.format.extent1-10cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationPneumonia. 2024, vol. 16, issue 1, p. 1-10.en
dc.identifier.doi10.1186/s41479-023-00123-7cs
dc.identifier.issn2200-6133cs
dc.identifier.orcid0000-0003-1849-5390cs
dc.identifier.other187604cs
dc.identifier.scopus23011250200cs
dc.identifier.urihttps://hdl.handle.net/11012/245495
dc.language.isoencs
dc.publisherBioMed Centralcs
dc.relation.ispartofPneumoniacs
dc.relation.urihttps://pneumonia.biomedcentral.com/articles/10.1186/s41479-023-00123-7cs
dc.rightsCreative Commons Attribution 4.0 Internationalcs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/2200-6133/cs
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/cs
dc.subjectPost-covid syndromeen
dc.subjectPulmonary fbrosisen
dc.subjectCorticosteroidsen
dc.subjectstatisticsen
dc.titleThe effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvementen
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen
sync.item.dbidVAV-187604en
sync.item.dbtypeVAVen
sync.item.insts2024.05.13 12:45:49en
sync.item.modts2024.05.13 12:14:00en
thesis.grantorVysoké učení technické v Brně. Fakulta elektrotechniky a komunikačních technologií. Ústav telekomunikacícs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s41479023001237.pdf
Size:
752.77 KB
Format:
Adobe Portable Document Format
Description:
file s41479023001237.pdf
Download
Collections
Ústav telekomunikací